Skip to content

Group-based Cardiac Telerehabilitation and Its Effectiveness

Group-based Cardiac Telerehabilitation and Its Effectiveness

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05923580
Enrollment
198
Registered
2023-06-28
Start date
2023-08-01
Completion date
2025-12-01
Last updated
2024-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Coronary artery disease, Cardiac telerehabilitation, Quality of life, Adherence to treatment, Lifestyle change

Brief summary

Cardiovascular diseases (CVD) and coronary artery diseases (CAD) are the most common cause of death worldwide. After an acute cardiac event, prevention of new cardiac events is essential and reduces suffering. Group-based cardiac telerehabilitation (CTR) refers to the use of information and communication technologies for rehabilitation purposes in promoting CAD patients´ health.

Detailed description

This study aims to assess the group-based cardiac telerehabilitation model and its effectiveness. The data is collected from two University hospitals in Finland. Patients with coronary heart disease two months after percutaneous coronary intervention (N=198) are invited to the study. All the participants are being treated in a healthcare unit that uses digital care pathways for coronary patients. Patients can choose the usual care or group-based cardiac telerehabilitation as follow-up care. All the patients are invited to the study after the chosen follow-up care (telerehabilitation or usual care). Patients will be allocated into two groups: The telerehabilitation group is the intervention group and the usual care group is the control group. Quality of life, adherence to treatment, and lifestyle changes are measured at the baseline and 3, 6, and 12 after the intervention baseline.

Interventions

BEHAVIORALGroup- based cardiac telerehabilitation

Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.

Sponsors

Oulu University Hospital
CollaboratorOTHER
Kuopio University Hospital
CollaboratorOTHER
University of Eastern Finland
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

All the participants are being treated in a healthcare unit that uses digital care pathways for coronary patients. Patients can choose the usual care or group-based cardiac telerehabilitation as follow-up care. All the patients are invited to the study after the chosen follow-up care (telerehabilitation or usual care)

Intervention model description

Participants' quality of life (measured with the 15D quality of life instrument), lifestyle changes, and adherence to treatment will be measured using quantitative methods with a quasi-experimental research design and interrupted time- series design. The power analysis for the study will be conducted using Finnish population norms for the 15D instrument. The sample size will be 198 cardiac rehabilitation participants (N=198), with 99 participants in the intervention group (N=99) and 99 participants in the control group (N=99). With this sample size, a power of over 80% (p=0.05) will be achieved to detect a difference of 0.12 (0.95 vs. 0.83, SD=0.3) in quality of life between the groups.

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants must have patients with coronary heart disease two months after percutaneous coronary intervention. * Participants must have ≥18 years of age, and ≤100 years of age * Participants are being treated in a healthcare unit that uses digital care pathways for coronary patients.

Exclusion criteria

* Participants must not have coronary artery disease diagnosed. * Participants have been in other operations than percutaneous coronary intervention.

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline in The Adherence to Medication at 12 MonthsBaseline and 12 MonthsAdherence to Medication- instrument is a generic, self-administered instrument. The questionnaire contains items of adherence to medication, which are rated on a 5-point Likert scale ('definitely disagree' to 'definitely agree').
Change from Baseline in The health-related quality of life at 12 MonthsBaseline and 12 Months15D The health-related quality of life (HRQoL) instrument is a generic, comprehensive (15-dimensional), self-administered instrument for adults (age 16+ years). It combines the advantages of a profile and a preference-based, single index measure. A set of utility or preference weights is used to generate the 15D score (single index number) on a 0-1 scale, representing the overall HRQoL (0 = being dead, 0.0162 = being unconscious or comatose, 1 = no problems on any dimension = 'full' HRQOL). Change = (Month 12 score- Baseline score).
Change from Baseline in The Adherence to Treatment at 12 MonthsBaseline and 12 MonthsAdherence to Treatment is a self-assessment instrument designed to describe adherence to treatment of long-term conditions. The questionnaire contains 38 items of adherence to treatment, which are rated on a 5-point Likert scale ('definitely disagree' to 'definitely agree').
Change from Baseline in Health and Well- being at 12 MonthsBaseline and 12 MonthsHealth and well-being - the instrument is a generic, self-administered instrument. The questionnaire contains items on the factors influencing health and well-being (smoking, use of alcohol, eating habits, physical activity, sleep), which are rated on a 5-point Likert scale ('definitely disagree' to 'definitely agree').

Countries

Finland

Contacts

Primary ContactRenuka J Jacobsson, MHSc
renukaj@uef.fi+358504111741
Backup ContactPäivi Kankkunen, docent
paivi.kankkunen@uef.fi+358 29 4454435

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026